Pharma major Lupin Ltd. announced that its Australian subsidiary Generic Health Pty. Ltd. has acquired the worldwide rights to the Goanna brand and the complete range of premium therapeutic oils, rubs and ointments marketed under the brand.

Vinod Dhawan, president, AAMLA and business development, Lupin Ltd said “We are very excited with our third major global brand acquisition in less than two years. The Goanna acquisition demonstrates Lupin's success in, and commitment to, building its brand franchise and equity globally. It underlines Lupin's differentiated strategy for select markets and is a strategic step that will help us strengthen and grow our brand business. Since Goanna is an in-market, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our topline in the coming years.”

Founded in 1910, the Goanna brand has been trusted by generations of Australians to provide effective relief of muscular aches and pains and other conditions such as arthritis.

Lupin Ltd through its subsidiary Generic Health is excited to add this heritage brand to the existing portfolio of quality prescription and over-the-counter products and looks forward to continuing the brand's rich tradition of excellence. The company also intends to add a number of exciting brand extensions to the range that will further reinforce the position of this tried and tested range of products in the Australian market.

The brand is being sold by around 83 per cent pharmacies in Australia, which would also go a long way in increasing its reach in the market. Generic Health has worked closely with Aspen Pharmacare to ensure a smooth transition of ownership for its customers and a seamless transition is already underway.

Lupin Ltd. is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs and today it has significant presence in cardiovasculars (prils and statins), diabetology, asthama, paediatrics, CNS, GI, anti-infectives and NSAID's in addition to holding global leadership positions in the anti-TB and cephalosporins space.